Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013
•Rise of annual AML cases is caused by demographic ageing and not by an increase of age-specific risks.•AML classification improves over time but diagnostics and reporting are less accurate with increasing age.•Increase of allogeneic HSCT and clinical trial activities in elderly AML patients aged 65...
Gespeichert in:
| Veröffentlicht in: | Cancer epidemiology 2018-02, Vol.52, p.55-62 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 62 |
|---|---|
| container_issue | |
| container_start_page | 55 |
| container_title | Cancer epidemiology |
| container_volume | 52 |
| creator | Schnegg-Kaufmann, Annatina Feller, Anita Baldomero, Helen Rovo, Alicia Manz, Markus G. Gregor, Michael Efthymiou, Anna Bargetzi, Mario Hess, Urs Spertini, Olivier Chalandon, Yves Passweg, Jakob R. Stussi, Georg Arndt, Volker Bonadies, Nicolas |
| description | •Rise of annual AML cases is caused by demographic ageing and not by an increase of age-specific risks.•AML classification improves over time but diagnostics and reporting are less accurate with increasing age.•Increase of allogeneic HSCT and clinical trial activities in elderly AML patients aged 65–74yrs.•Improvement of relative survival for elderly AML patients caused by general changes in management.•Therapeutic nihilism in elderly AML patients is not justifiable.
Acute Myeloid Leukaemia (AML) is a rare and heterogeneous haematological malignancy with increasing incidence in the elderly. We performed a population-based, observational analysis of AML cases reported to the Cantonal Cancer Registries in Switzerland. Data was aggregated by the National Institute for Epidemiology and Cancer Registration and stratified for the two time periods 2001–2007 and 2008–2013. Overall, 2351 new AML cases were registered with a stable age-standardised incidence rate (3.0 [95 CI: 2.8-3.2] per 100,000 person-years). This indicates that our observed raise of annual AML cases (+10.9%) is mainly related to demographic ageing and not to an increase of age-specific risks. The fraction of non-classifiable AML cases decreased over time (54.6% to 41.8%) but remained high in elderly patients (65–74yrs: 44%; 75–84yrs: 54.2%, 85+yrs: 59.1%), suggesting less accurate diagnostics and reporting with increasing age. 5yrs relative survival (RS) correlated with AML risk class (favorable: 61.7%-68.4%; adverse risk: 11.4%-21.9%) and age ( |
| doi_str_mv | 10.1016/j.canep.2017.11.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1975034776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1877782117301996</els_id><sourcerecordid>2007509549</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-4a2730b60ecf5076df3ac998244e840f74af94a04b110a6806b5557b13698e8d3</originalsourceid><addsrcrecordid>eNp9kTFv1TAUhSNERUvhFyAhSywsSa9jJ04GBlQVqFSpAyCxWY5z8_AjiYOdpHr8of5NbnilAwOTLfvzOcf3JMkrDhkHXl7sM2tGnLIcuMo4zwCqJ8kZr5RKVSW-PX3c5_w0eR7jHqAsOS-eJad5neeCgzxL7q-HKfgVBxxn5jsWsDezW5HFJaxuNT1zI8O-xdAf2ERXxEV25-bvzNhlRjYcsPeuZT0uPwwOzjDSCjs37lgX_MAmPy2bpB_TxkRsGYW2GMho5-IcHMbN4TMp_iIPM7aswfkOcWQ5AGfbAX1QvEhOOtNHfPmwnidfP1x9ufyU3tx-vL58f5NaUak5lSZXApoS0HYFqLLthLF1XeVSYiWhU9J0tTQgG87BlBWUTVEUquGirCusWnGevD3q0lR-LhhnPbhosadk6Jeoea0KEFKpktA3_6B7v4SR0mmKTlhdyJoocaRs8DEG7PQU3GDCQXPQW496r__0qLceNeeaeqRXrx-0l2bA9vHN3-IIeHcEkIaxOgw6WurGYusC2lm33v3X4DdBzbEH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2007509549</pqid></control><display><type>article</type><title>Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Schnegg-Kaufmann, Annatina ; Feller, Anita ; Baldomero, Helen ; Rovo, Alicia ; Manz, Markus G. ; Gregor, Michael ; Efthymiou, Anna ; Bargetzi, Mario ; Hess, Urs ; Spertini, Olivier ; Chalandon, Yves ; Passweg, Jakob R. ; Stussi, Georg ; Arndt, Volker ; Bonadies, Nicolas</creator><creatorcontrib>Schnegg-Kaufmann, Annatina ; Feller, Anita ; Baldomero, Helen ; Rovo, Alicia ; Manz, Markus G. ; Gregor, Michael ; Efthymiou, Anna ; Bargetzi, Mario ; Hess, Urs ; Spertini, Olivier ; Chalandon, Yves ; Passweg, Jakob R. ; Stussi, Georg ; Arndt, Volker ; Bonadies, Nicolas ; the NICER Working Group ; NICER Working Group</creatorcontrib><description>•Rise of annual AML cases is caused by demographic ageing and not by an increase of age-specific risks.•AML classification improves over time but diagnostics and reporting are less accurate with increasing age.•Increase of allogeneic HSCT and clinical trial activities in elderly AML patients aged 65–74yrs.•Improvement of relative survival for elderly AML patients caused by general changes in management.•Therapeutic nihilism in elderly AML patients is not justifiable.
Acute Myeloid Leukaemia (AML) is a rare and heterogeneous haematological malignancy with increasing incidence in the elderly. We performed a population-based, observational analysis of AML cases reported to the Cantonal Cancer Registries in Switzerland. Data was aggregated by the National Institute for Epidemiology and Cancer Registration and stratified for the two time periods 2001–2007 and 2008–2013. Overall, 2351 new AML cases were registered with a stable age-standardised incidence rate (3.0 [95 CI: 2.8-3.2] per 100,000 person-years). This indicates that our observed raise of annual AML cases (+10.9%) is mainly related to demographic ageing and not to an increase of age-specific risks. The fraction of non-classifiable AML cases decreased over time (54.6% to 41.8%) but remained high in elderly patients (65–74yrs: 44%; 75–84yrs: 54.2%, 85+yrs: 59.1%), suggesting less accurate diagnostics and reporting with increasing age. 5yrs relative survival (RS) correlated with AML risk class (favorable: 61.7%-68.4%; adverse risk: 11.4%-21.9%) and age (<65yrs: 42.6–43.3%; 75–84yrs: 2.0-3.0%), but improved only modestly overall (19.2% to 23.3%). Interestingly, we identified a significant improvement of RS in patients aged 65–74yrs (5yrs: 5.2% to 13.5%; p<0.001). As surrogate for changes in management, we found an increase of allogeneic haematopoietic stem cell transplantations (1.4 to 7%) and clinical trial activities (25 to 29%) for elderly AML patients during the observation period. Our analysis indicates that recent progress made in management of elderly AML patients results in an improvement of survival on a population-based level in Switzerland and that therapeutic nihilism is not justifiable.</description><identifier>ISSN: 1877-7821</identifier><identifier>EISSN: 1877-783X</identifier><identifier>DOI: 10.1016/j.canep.2017.11.008</identifier><identifier>PMID: 29223104</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Acute myeloid leukaemia ; Acute myeloid leukemia ; Adolescent ; Adult ; Age ; Age Factors ; Aged ; Aged, 80 and over ; Cancer ; Cancer therapies ; Chemotherapy ; Child ; Child, Preschool ; Classification ; Demographics ; Disease ; DNA methylation ; Epidemiology ; Female ; Geriatrics ; Hematology ; Hematopoietic stem cells ; Humans ; Incidence ; Infant ; Infant, Newborn ; Leukemia ; Leukemia, Myeloid, Acute - epidemiology ; Leukemia, Myeloid, Acute - mortality ; Leukemia, Myeloid, Acute - therapy ; Male ; Malignancy ; Medical prognosis ; Middle Aged ; Mortality ; Older people ; Patients ; Population ; Prognosis ; Registration ; Registries - statistics & numerical data ; Risk Factors ; Survival ; Survival Rate ; Switzerland - epidemiology ; Time Factors ; Trends ; Tumors ; Young Adult</subject><ispartof>Cancer epidemiology, 2018-02, Vol.52, p.55-62</ispartof><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-4a2730b60ecf5076df3ac998244e840f74af94a04b110a6806b5557b13698e8d3</citedby><cites>FETCH-LOGICAL-c387t-4a2730b60ecf5076df3ac998244e840f74af94a04b110a6806b5557b13698e8d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2007509549?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29223104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schnegg-Kaufmann, Annatina</creatorcontrib><creatorcontrib>Feller, Anita</creatorcontrib><creatorcontrib>Baldomero, Helen</creatorcontrib><creatorcontrib>Rovo, Alicia</creatorcontrib><creatorcontrib>Manz, Markus G.</creatorcontrib><creatorcontrib>Gregor, Michael</creatorcontrib><creatorcontrib>Efthymiou, Anna</creatorcontrib><creatorcontrib>Bargetzi, Mario</creatorcontrib><creatorcontrib>Hess, Urs</creatorcontrib><creatorcontrib>Spertini, Olivier</creatorcontrib><creatorcontrib>Chalandon, Yves</creatorcontrib><creatorcontrib>Passweg, Jakob R.</creatorcontrib><creatorcontrib>Stussi, Georg</creatorcontrib><creatorcontrib>Arndt, Volker</creatorcontrib><creatorcontrib>Bonadies, Nicolas</creatorcontrib><creatorcontrib>the NICER Working Group</creatorcontrib><creatorcontrib>NICER Working Group</creatorcontrib><title>Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013</title><title>Cancer epidemiology</title><addtitle>Cancer Epidemiol</addtitle><description>•Rise of annual AML cases is caused by demographic ageing and not by an increase of age-specific risks.•AML classification improves over time but diagnostics and reporting are less accurate with increasing age.•Increase of allogeneic HSCT and clinical trial activities in elderly AML patients aged 65–74yrs.•Improvement of relative survival for elderly AML patients caused by general changes in management.•Therapeutic nihilism in elderly AML patients is not justifiable.
Acute Myeloid Leukaemia (AML) is a rare and heterogeneous haematological malignancy with increasing incidence in the elderly. We performed a population-based, observational analysis of AML cases reported to the Cantonal Cancer Registries in Switzerland. Data was aggregated by the National Institute for Epidemiology and Cancer Registration and stratified for the two time periods 2001–2007 and 2008–2013. Overall, 2351 new AML cases were registered with a stable age-standardised incidence rate (3.0 [95 CI: 2.8-3.2] per 100,000 person-years). This indicates that our observed raise of annual AML cases (+10.9%) is mainly related to demographic ageing and not to an increase of age-specific risks. The fraction of non-classifiable AML cases decreased over time (54.6% to 41.8%) but remained high in elderly patients (65–74yrs: 44%; 75–84yrs: 54.2%, 85+yrs: 59.1%), suggesting less accurate diagnostics and reporting with increasing age. 5yrs relative survival (RS) correlated with AML risk class (favorable: 61.7%-68.4%; adverse risk: 11.4%-21.9%) and age (<65yrs: 42.6–43.3%; 75–84yrs: 2.0-3.0%), but improved only modestly overall (19.2% to 23.3%). Interestingly, we identified a significant improvement of RS in patients aged 65–74yrs (5yrs: 5.2% to 13.5%; p<0.001). As surrogate for changes in management, we found an increase of allogeneic haematopoietic stem cell transplantations (1.4 to 7%) and clinical trial activities (25 to 29%) for elderly AML patients during the observation period. Our analysis indicates that recent progress made in management of elderly AML patients results in an improvement of survival on a population-based level in Switzerland and that therapeutic nihilism is not justifiable.</description><subject>Acute myeloid leukaemia</subject><subject>Acute myeloid leukemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Classification</subject><subject>Demographics</subject><subject>Disease</subject><subject>DNA methylation</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Geriatrics</subject><subject>Hematology</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - epidemiology</subject><subject>Leukemia, Myeloid, Acute - mortality</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Male</subject><subject>Malignancy</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Older people</subject><subject>Patients</subject><subject>Population</subject><subject>Prognosis</subject><subject>Registration</subject><subject>Registries - statistics & numerical data</subject><subject>Risk Factors</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Switzerland - epidemiology</subject><subject>Time Factors</subject><subject>Trends</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>1877-7821</issn><issn>1877-783X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kTFv1TAUhSNERUvhFyAhSywsSa9jJ04GBlQVqFSpAyCxWY5z8_AjiYOdpHr8of5NbnilAwOTLfvzOcf3JMkrDhkHXl7sM2tGnLIcuMo4zwCqJ8kZr5RKVSW-PX3c5_w0eR7jHqAsOS-eJad5neeCgzxL7q-HKfgVBxxn5jsWsDezW5HFJaxuNT1zI8O-xdAf2ERXxEV25-bvzNhlRjYcsPeuZT0uPwwOzjDSCjs37lgX_MAmPy2bpB_TxkRsGYW2GMho5-IcHMbN4TMp_iIPM7aswfkOcWQ5AGfbAX1QvEhOOtNHfPmwnidfP1x9ufyU3tx-vL58f5NaUak5lSZXApoS0HYFqLLthLF1XeVSYiWhU9J0tTQgG87BlBWUTVEUquGirCusWnGevD3q0lR-LhhnPbhosadk6Jeoea0KEFKpktA3_6B7v4SR0mmKTlhdyJoocaRs8DEG7PQU3GDCQXPQW496r__0qLceNeeaeqRXrx-0l2bA9vHN3-IIeHcEkIaxOgw6WurGYusC2lm33v3X4DdBzbEH</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Schnegg-Kaufmann, Annatina</creator><creator>Feller, Anita</creator><creator>Baldomero, Helen</creator><creator>Rovo, Alicia</creator><creator>Manz, Markus G.</creator><creator>Gregor, Michael</creator><creator>Efthymiou, Anna</creator><creator>Bargetzi, Mario</creator><creator>Hess, Urs</creator><creator>Spertini, Olivier</creator><creator>Chalandon, Yves</creator><creator>Passweg, Jakob R.</creator><creator>Stussi, Georg</creator><creator>Arndt, Volker</creator><creator>Bonadies, Nicolas</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20180201</creationdate><title>Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013</title><author>Schnegg-Kaufmann, Annatina ; Feller, Anita ; Baldomero, Helen ; Rovo, Alicia ; Manz, Markus G. ; Gregor, Michael ; Efthymiou, Anna ; Bargetzi, Mario ; Hess, Urs ; Spertini, Olivier ; Chalandon, Yves ; Passweg, Jakob R. ; Stussi, Georg ; Arndt, Volker ; Bonadies, Nicolas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-4a2730b60ecf5076df3ac998244e840f74af94a04b110a6806b5557b13698e8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acute myeloid leukaemia</topic><topic>Acute myeloid leukemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Classification</topic><topic>Demographics</topic><topic>Disease</topic><topic>DNA methylation</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Geriatrics</topic><topic>Hematology</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - epidemiology</topic><topic>Leukemia, Myeloid, Acute - mortality</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Male</topic><topic>Malignancy</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Older people</topic><topic>Patients</topic><topic>Population</topic><topic>Prognosis</topic><topic>Registration</topic><topic>Registries - statistics & numerical data</topic><topic>Risk Factors</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Switzerland - epidemiology</topic><topic>Time Factors</topic><topic>Trends</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schnegg-Kaufmann, Annatina</creatorcontrib><creatorcontrib>Feller, Anita</creatorcontrib><creatorcontrib>Baldomero, Helen</creatorcontrib><creatorcontrib>Rovo, Alicia</creatorcontrib><creatorcontrib>Manz, Markus G.</creatorcontrib><creatorcontrib>Gregor, Michael</creatorcontrib><creatorcontrib>Efthymiou, Anna</creatorcontrib><creatorcontrib>Bargetzi, Mario</creatorcontrib><creatorcontrib>Hess, Urs</creatorcontrib><creatorcontrib>Spertini, Olivier</creatorcontrib><creatorcontrib>Chalandon, Yves</creatorcontrib><creatorcontrib>Passweg, Jakob R.</creatorcontrib><creatorcontrib>Stussi, Georg</creatorcontrib><creatorcontrib>Arndt, Volker</creatorcontrib><creatorcontrib>Bonadies, Nicolas</creatorcontrib><creatorcontrib>the NICER Working Group</creatorcontrib><creatorcontrib>NICER Working Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schnegg-Kaufmann, Annatina</au><au>Feller, Anita</au><au>Baldomero, Helen</au><au>Rovo, Alicia</au><au>Manz, Markus G.</au><au>Gregor, Michael</au><au>Efthymiou, Anna</au><au>Bargetzi, Mario</au><au>Hess, Urs</au><au>Spertini, Olivier</au><au>Chalandon, Yves</au><au>Passweg, Jakob R.</au><au>Stussi, Georg</au><au>Arndt, Volker</au><au>Bonadies, Nicolas</au><aucorp>the NICER Working Group</aucorp><aucorp>NICER Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013</atitle><jtitle>Cancer epidemiology</jtitle><addtitle>Cancer Epidemiol</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>52</volume><spage>55</spage><epage>62</epage><pages>55-62</pages><issn>1877-7821</issn><eissn>1877-783X</eissn><abstract>•Rise of annual AML cases is caused by demographic ageing and not by an increase of age-specific risks.•AML classification improves over time but diagnostics and reporting are less accurate with increasing age.•Increase of allogeneic HSCT and clinical trial activities in elderly AML patients aged 65–74yrs.•Improvement of relative survival for elderly AML patients caused by general changes in management.•Therapeutic nihilism in elderly AML patients is not justifiable.
Acute Myeloid Leukaemia (AML) is a rare and heterogeneous haematological malignancy with increasing incidence in the elderly. We performed a population-based, observational analysis of AML cases reported to the Cantonal Cancer Registries in Switzerland. Data was aggregated by the National Institute for Epidemiology and Cancer Registration and stratified for the two time periods 2001–2007 and 2008–2013. Overall, 2351 new AML cases were registered with a stable age-standardised incidence rate (3.0 [95 CI: 2.8-3.2] per 100,000 person-years). This indicates that our observed raise of annual AML cases (+10.9%) is mainly related to demographic ageing and not to an increase of age-specific risks. The fraction of non-classifiable AML cases decreased over time (54.6% to 41.8%) but remained high in elderly patients (65–74yrs: 44%; 75–84yrs: 54.2%, 85+yrs: 59.1%), suggesting less accurate diagnostics and reporting with increasing age. 5yrs relative survival (RS) correlated with AML risk class (favorable: 61.7%-68.4%; adverse risk: 11.4%-21.9%) and age (<65yrs: 42.6–43.3%; 75–84yrs: 2.0-3.0%), but improved only modestly overall (19.2% to 23.3%). Interestingly, we identified a significant improvement of RS in patients aged 65–74yrs (5yrs: 5.2% to 13.5%; p<0.001). As surrogate for changes in management, we found an increase of allogeneic haematopoietic stem cell transplantations (1.4 to 7%) and clinical trial activities (25 to 29%) for elderly AML patients during the observation period. Our analysis indicates that recent progress made in management of elderly AML patients results in an improvement of survival on a population-based level in Switzerland and that therapeutic nihilism is not justifiable.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>29223104</pmid><doi>10.1016/j.canep.2017.11.008</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1877-7821 |
| ispartof | Cancer epidemiology, 2018-02, Vol.52, p.55-62 |
| issn | 1877-7821 1877-783X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1975034776 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Acute myeloid leukaemia Acute myeloid leukemia Adolescent Adult Age Age Factors Aged Aged, 80 and over Cancer Cancer therapies Chemotherapy Child Child, Preschool Classification Demographics Disease DNA methylation Epidemiology Female Geriatrics Hematology Hematopoietic stem cells Humans Incidence Infant Infant, Newborn Leukemia Leukemia, Myeloid, Acute - epidemiology Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - therapy Male Malignancy Medical prognosis Middle Aged Mortality Older people Patients Population Prognosis Registration Registries - statistics & numerical data Risk Factors Survival Survival Rate Switzerland - epidemiology Time Factors Trends Tumors Young Adult |
| title | Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A58%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20of%20relative%20survival%20in%20elderly%20patients%20with%20acute%20myeloid%20leukaemia%20emerging%20from%20population-based%20cancer%20registries%20in%20Switzerland%20between%202001%20and%202013&rft.jtitle=Cancer%20epidemiology&rft.au=Schnegg-Kaufmann,%20Annatina&rft.aucorp=the%20NICER%20Working%20Group&rft.date=2018-02-01&rft.volume=52&rft.spage=55&rft.epage=62&rft.pages=55-62&rft.issn=1877-7821&rft.eissn=1877-783X&rft_id=info:doi/10.1016/j.canep.2017.11.008&rft_dat=%3Cproquest_cross%3E2007509549%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2007509549&rft_id=info:pmid/29223104&rft_els_id=S1877782117301996&rfr_iscdi=true |